title: Oral Chinese herbal medicine combined with pharmacotherapy for psoriasis vulgaris: a systematic review.
abstract: Clinically, oral Chinese herbal medicine (CHM) is widely used in the treatment of psoriasis. This review evaluates the effects of oral CHM in combination with pharmacotherapy for psoriasis vulgaris. The Cochrane Library, PubMed, Embase, CINAHL, CNKI, and CQVIP were searched from their inceptions to November 2012. Randomized controlled trials (RCTs) investigating CHM plus pharmacotherapy compared to pharmacotherapy were included. Data were analyzed using Review Manager 5.1.0. Seventeen RCTs were included, conducted in China, and employed a diversity of both herbal medicines and pharmacotherapies. When the meta-analyses were restricted to studies that used a well-known pharmacotherapy as the comparator with 60% or greater clinical improvement in psoriasis as the outcome, five studies used oral acitretin, one used topical calcipotriol, and one used topical clobetasol propionate as control interventions. At the end of treatment, there was a benefit for the pooled result of the five studies that compared CHM plus acitretin with acitretin alone and no serious adverse events were reported. However, none of these studies was blind, so there is considerable risk of bias in this result. In addition, there was inadequate reporting of longer-term results, so it remains unclear whether the reported effect could be maintained or whether the prolonged use of the CHM in conjunction with acitretin would be safe. The main plants used in these studies, Rehmannia glutinosa root, Salvia miltiorrhiza root, and Lithospermum erythrorhizon root, have shown anti-inflammatory and/or antiproliferative effects in experimental studies. These actions may at least partially explain the observed results.
authors.affiliation: Traditional & Complementary Medicine Research Program, Health Innovations Research Institute, School of Health Sciences, RMIT University, Bundoora Campus, Vic., Australia.
authors.forename: Claire Shuiqing
authors.initials: CS
authors.lastname: Zhang
authors.forename: Jason Jingjie
authors.initials: JJ
authors.lastname: Yu
authors.forename: Shefton
authors.initials: S
authors.lastname: Parker
authors.forename: Anthony Lin
authors.initials: AL
authors.lastname: Zhang
authors.forename: Brian
authors.initials: B
authors.lastname: May
authors.forename: Chuanjian
authors.initials: C
authors.lastname: Lu
authors.forename: Charlie Changli
authors.initials: CC
authors.lastname: Xue
mesh_terms: D017255:Acitretin / Q000627:therapeutic use*; D004359:Drug Therapy, Combination / Q000009:adverse effects; D004365:Drugs, Chinese Herbal / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007641:Keratolytic Agents / Q000627:therapeutic use*; D029684:Lithospermum; D008517:Phytotherapy; D018517:Plant Roots; D011565:Psoriasis / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic; D032267:Rehmannia; D027561:Salvia miltiorrhiza
chemical_list: D004365:Drugs, Chinese Herbal; D007641:Keratolytic Agents; D017255:Acitretin